NO960551L - Antistoff basert behandling av HIV infeksjon - Google Patents

Antistoff basert behandling av HIV infeksjon

Info

Publication number
NO960551L
NO960551L NO960551A NO960551A NO960551L NO 960551 L NO960551 L NO 960551L NO 960551 A NO960551 A NO 960551A NO 960551 A NO960551 A NO 960551A NO 960551 L NO960551 L NO 960551L
Authority
NO
Norway
Prior art keywords
hiv
complexes
antibody
complement
antigen
Prior art date
Application number
NO960551A
Other languages
English (en)
Other versions
NO960551D0 (no
Inventor
Robert B Naso
Original Assignee
Univax Biolog Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univax Biolog Inc filed Critical Univax Biolog Inc
Publication of NO960551L publication Critical patent/NO960551L/no
Publication of NO960551D0 publication Critical patent/NO960551D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En metode for å redusere eller forhindre progressjonen av HIV infeksjon i et HIV-eksponert individ, og forhindre HIV-infeksjon i et individ som har en risiko for HIV-. i. infeksjon, omfatter tilveiebringing av antistoffantigen kompleks eller. antistoff:antigen:komplementkompleks til individet i titere som er tilstrekkelig for på konkurrerende måte å inhibere HIV-komplekscr fra og binde celler via Fc reseptorer eller komplementreseptorer i lymfoid vev. Denne metoden anvender antistoffer som blir bundet til cellulære antigener for å danne antigen:antistoff komplekser og/eller antigen:antistoff:komplementkomplekser, som igjen inhiberer eller forhindrer bindingen av HIV:antistoff komplekser eller HIV:antistoff:komplementkomplekser eller HIV:komplementkomplekser til cellene i lymfoid vev. Ved å hemme konsentrasjonen. i av HIV komplekser bundet til lymfevev reduseres belastningen av viralt infiserte celler. og øker effektiviteten til anti-retrovirale midler og øker virus inaktiveringen i blodstrømmen. Den reduserte konsentrasjonen eller fraværet av HIV i lymfevev hindrer infeksjon av CD4+ T celler deri.
NO960551A 1993-08-13 1996-02-12 Antistoff basert behandling av HIV infeksjon NO960551D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10558493A 1993-08-13 1993-08-13
PCT/US1994/008312 WO1995005196A1 (en) 1993-08-13 1994-08-10 Antibody-based treatment of hiv infection

Publications (2)

Publication Number Publication Date
NO960551L true NO960551L (no) 1996-02-12
NO960551D0 NO960551D0 (no) 1996-02-12

Family

ID=22306655

Family Applications (1)

Application Number Title Priority Date Filing Date
NO960551A NO960551D0 (no) 1993-08-13 1996-02-12 Antistoff basert behandling av HIV infeksjon

Country Status (5)

Country Link
EP (1) EP0715522A1 (no)
AU (1) AU703324B2 (no)
CA (1) CA2169370A1 (no)
NO (1) NO960551D0 (no)
WO (1) WO1995005196A1 (no)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993812A (en) * 1995-09-14 1999-11-30 Cangene Corporation Method of delaying the progression of an infection with the human immunodeficiency virus
JP2009525319A (ja) 2006-02-02 2009-07-09 ライナット ニューロサイエンス コーポレイション ｔｒｋＢアンタゴニストを投与することにより肥満を治療する方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1168152A (en) 1981-10-20 1984-05-29 Winnipeg Rh Institute Inc. (The) Process for preparing human plasma fractions containing immune globulin (igg)
WO1991006575A1 (en) * 1989-11-03 1991-05-16 Repligen Corporation Hiv-1 specific human monoclonal antibody

Also Published As

Publication number Publication date
AU703324B2 (en) 1999-03-25
AU7550494A (en) 1995-03-14
NO960551D0 (no) 1996-02-12
EP0715522A1 (en) 1996-06-12
CA2169370A1 (en) 1995-02-23
WO1995005196A1 (en) 1995-02-23

Similar Documents

Publication Publication Date Title
Nara et al. Persistent infection of chimpanzees with human immunodeficiency virus: serological responses and properties of reisolated viruses
Schols et al. Dextran sulfate and other polyanionic anti-HIV compounds specifically interact with the viral gp120 glycoprotein expressed by T-cells persistently infected with HIV-1
Kohler et al. Clonal dominance: cause for a limited and failing immune response to HIV-1 infection and vaccination
Daar et al. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates.
Pahwa et al. Influence of the human T-lymphotropic virus/lymphadenopathy-associated virus on functions of human lymphocytes: evidence for immunosuppressive effects and polyclonal B-cell activation by banded viral preparations.
Li et al. Synergistic neutralization of simian-human immunodeficiency virus SHIV-vpu+ by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins
Chan et al. Protection in simian immunodeficiency virus-vaccinated monkeys correlates with anti-HLA class I antibody response.
Schmitz et al. Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59.
Byrn et al. Characterization of in vitro inhibition of human immunodeficiency virus by purified recombinant CD4
Burkly et al. Synergistic inhibition of human immunodeficiency virus type 1 envelope glycoprotein-mediated cell fusion and infection by an antibody to CD4 domain 2 in combination with anti-gp120 antibodies
Lee et al. Anti-HIV-1 antibody-dependent cellular cytotoxicity: is there more to antibodies than neutralization?
EP1003552A4 (en) ANTIBODIES DIRECTED AGAINST LO-CD2a AND USE THEREOF TO INHIBIT THE ACTIVATION AND PROLIFERATION OF T-LYMPHOCYTES
Oxenius et al. Variable fate of virus‐specific CD4+ T cells during primary HIV‐1 infection
Ohlin et al. Human monoclonal antibodies against a recombinant HIV envelope antigen produced by primary in vitro immunization. Characterization and epitope mapping
Duval et al. A bispecific antibody composed of a nonneutralizing antibody to the gp41 immunodominant region and an anti-CD89 antibody directs broad human immunodeficiency virus destruction by neutrophils
Carpenter et al. Recent insights into Fc-mediated effector responses to HIV-1
US20100291102A1 (en) Therapeutic Agent
Kennedy et al. Use of a resin-bound synthetic peptide for identifying a neutralizing antigenic determinant associated with the human immunodeficiency virus envelope.
Burrer et al. Neutralizing as well as non-neutralizing polyclonal immunoglobulin (Ig) G from infected patients capture HIV-1 via antibodies directed against the principal immunodominant domain of gp41
AU620804B2 (en) Novel vaccines
ATE335835T1 (de) Antikörper gegen einen komplex aus cd4 und einer chemokinrezeptordomäne, sowie deren verwendung gegen hiv infektionen
ATE464909T1 (de) Humane anti-chemokinrezeptoren igm antikörper
NO960551L (no) Antistoff basert behandling av HIV infeksjon
Grasberger et al. Harnessing immune cells to eliminate HIV reservoirs
Spruth et al. Neutralization of HIV type 1 by alloimmune sera derived from polytransfused patients